Search

everythinglearnresearchcommunity

for

Search:↓

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

A user reported a 50% increase in testosterone after 18 months of taking dutasteride for hair loss. The conversation includes skepticism about the reliability of single testosterone tests and questions about estrogen levels.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced side effects from finasteride and is considering switching to dutasteride, while also using pyrilutamide to protect hair follicles. They are seeking advice on whether to add RU58841 to their regimen.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

The conversation is about finding alternatives to Octa Sabal Plus for hair loss treatment. It mentions using ingredients like pumpkin seed oil, octacosanol, and soybean extract, but suggests finasteride as a more effective option.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

A user shared progress pictures 12 months after a hair transplant and daily use of dutasteride. The conversation discusses the quality of comparison photos and the use of hair fibers.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

User discusses using finasteride, ketoconazole, fish oil, nettle root, saw palmetto, emu oil, and plans to start minoxidil for hair loss. They report maintaining hair with minor side effects like slightly lower libido and watery semen.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and the potential of mesotherapy. The user experiences hair loss despite low DHT levels and considers localized dutasteride treatment, while others suggest consulting a dermatologist and exploring other causes like malabsorption.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.

An 18-year-old male stopped using finasteride due to side effects and plans to start topical dutasteride, considering it a potential solution with fewer side effects. He continues using minoxidil despite no noticeable results and is exploring other treatments like RU58841.

A user shared their successful hair regrowth journey using finasteride, oral minoxidil, and oral dutasteride, expressing gratitude for the support received. The conversation includes congratulations and encouragement from others.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

Chris Bumstead got a hair transplant at Now Hair Time, and the discussion focuses on why he chose a less reputable clinic despite having the means for a better one, with some suggesting it was for financial gain. The conversation also touches on concerns about the naturalness of the hairline and the potential impact of his steroid use on the transplant's success.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.